Actively Recruiting
Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus
Led by Todd C. Lee MD MPH FIDSA · Updated on 2025-12-10
330
Participants Needed
1
Research Sites
242 weeks
Total Duration
On this page
Sponsors
T
Todd C. Lee MD MPH FIDSA
Lead Sponsor
M
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.
CONDITIONS
Official Title
Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and/or aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable)
- Patient or healthcare proxy provide informed consent
You will not qualify if you...
- Death deemed imminent and inevitable within days or patient will be receiving palliative care with prognosis less than 90 days
- Patient requires intensive care but has a do not resuscitate order precluding transfer
- Polymicrobial bacteremia (excluding skin commensals or recognized contaminants)
- Rifampin-resistant organism
- History of severe allergy or adverse reaction to rifampin
- Important drug interactions with rifampin that cannot be safely managed
- Child Pugh Class C cirrhosis
- Clinician deems rifampin mandatory
- Patient has already received more than 3 days of rifampin at screening or more than 10 days total therapy
- Pregnancy or breastfeeding
- No reliable outpatient contact (telephone/email/text)
- Previously enrolled in the study
- Prior S. aureus bacteremia within the preceding 180 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
Montreal, Quebec, Canada, H4A4S1
Actively Recruiting
Research Team
L
Lina Petrella
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here